KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) EBT: 2011-2024

Historic EBT for Esperion Therapeutics (ESPR) over the last 14 years, with Dec 2024 value amounting to -$4.8 million.

  • Esperion Therapeutics' EBT fell 2.90% to -$32.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$107.8 million, marking a year-over-year decrease of 160.12%. This contributed to the annual value of -$4.8 million for FY2024, which is 97.74% up from last year.
  • As of FY2024, Esperion Therapeutics' EBT stood at -$4.8 million, which was up 97.74% from -$214.5 million recorded in FY2023.
  • Over the past 5 years, Esperion Therapeutics' EBT peaked at -$4.8 million during FY2024, and registered a low of -$273.1 million during FY2021.
  • For the 3-year period, Esperion Therapeutics' EBT averaged around -$151.9 million, with its median value being -$214.5 million (2023).
  • Per our database at Business Quant, Esperion Therapeutics' EBT plummeted by 89.55% in 2021 and then surged by 97.74% in 2024.
  • Over the past 5 years, Esperion Therapeutics' EBT (Yearly) stood at -$144.1 million in 2020, then tumbled by 89.55% to -$273.1 million in 2021, then climbed by 13.47% to -$236.3 million in 2022, then climbed by 9.21% to -$214.5 million in 2023, then spiked by 97.74% to -$4.8 million in 2024.